title: Ibopamine does not affect insulin resistance in patients with type I diabetes.
abstract: Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients.
authors.affiliation: Chair of Metabolic Disease, University of Pisa, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Benzi
authors.forename: F
authors.initials: F
authors.lastname: Sabino
authors.forename: A M
authors.initials: AM
authors.lastname: Ciccarone
authors.forename: P
authors.initials: P
authors.lastname: Cecchetti
authors.forename: G
authors.initials: G
authors.lastname: Di Cianni
authors.forename: V
authors.initials: V
authors.lastname: Cicchetti
authors.forename: R
authors.initials: R
authors.lastname: Navalesi
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002316:Cardiotonic Agents; D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents
chemical_list: D001786:Blood Glucose; D002316:Cardiotonic Agents; D007328:Insulin; D014665:Vasodilator Agents; C023487:ibopamine; D003846:Deoxyepinephrine